Anna F. Farago

Anna Farago is a thoracic oncologist and translational researcher specializing in ROS1-rearranged NSCLC and strategies to overcome acquired resistance to first-generation ROS1 inhibitors. Her work has characterized solvent-front resistance mutations in ROS1 and evaluated next-generation inhibitors including repotrectinib. She has contributed to multi-institutional studies characterizing the natural history and molecular evolution of ROS1-positive tumors. Her research bridges laboratory mechanistic studies and early-phase clinical trial design.